teysuno
nordic group b.v. - tegafur, gimeracil, oteracil - neoplażmi fl-istonku - aġenti antineoplastiċi - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.
spinraza
biogen netherlands b.v. - nusinersen sodium - atrofija muskolari, spinali - drogi oħra tas-sistema nervuża - spinraza hija indikata għat-trattament ta '5q atrofija muskolari spinali.
biktarvy
gilead sciences ireland uc - bictegravir, emtricitabine, tenofovir alafenamide, fumarate - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - biktarvy is indicated for the treatment of human immunodeficiency virus 1 (hiv 1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg i without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. (ara sezzjoni 5.
rxulti
otsuka pharmaceutical netherlands b.v. - brexpiprazole - skizofrenija - psikolettiċi - il-kura ta ' skizofrenja.
insulin aspart sanofi
sanofi winthrop industrie - insulin aspart - diabetes mellitus - drogi użati fid-dijabete - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
rekambys
janssen-cilag international nv - rilpivirine - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.
calquence
astrazeneca ab - acalabrutinib - lewkimja, linfokitika, kronika, b-Ċellula - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.
actelsar hct
actavis group hf - telmisartan, hydrochlorothiazide - essential hypertension - agents acting on the renin-angiotensin system, angiotensin ii antagonists and diuretics - trattament ta 'ipertensjoni essenzjali. actelsar hct kombinazzjoni b'doża fissa (40 mg telmisartan / 12. 5 mg ta ' hydrochlorothiazide) hi indikata f'adulti li l-pressjoni tad-demm ma tkunx ikkontrollata sew b'telmisartan waħdu. actelsar hct kombinazzjoni b'doża fissa (80 mg telmisartan / 12. 5 mg ta ' hydrochlorothiazide) hi indikata f'adulti li l-pressjoni tad-demm ma tkunx ikkontrollata sew b'telmisartan waħdu. actelsar hct kombinazzjoni b'doża fissa (80 mg telmisartan / 25 mg hydrochlorothiazide) hi indikata f'adulti li l-pressjoni tad-demm ma tkunx ikkontrollata adegwatament fuq actelsar hct 80 mg / 12. 5 mg (80 mg telmisartan / 12. 5 mg hydrochlorothiazide) jew adulti li qabel kienu stabbilizzati fuq telmisartan u hydrochlorothiazide mogħtija separatament.
benlysta
glaxosmithkline (ireland) limited - belimumab - lupus eritematoso, sistemiku - immunosoppressanti - benlysta huwa indikat bħala terapija add-on f'pazjenti b'età ta ' 5 snin u akbar bi attiva, awtoantikorpi pożittivi lupus eritematosus sistemika (sle) bil-livell għoli ta'attività tal-marda (e. , pożittivi kontra dsdna u baxxa jikkumplimentaw) minkejja terapija standard. benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.
varuby
tesaro bio netherlands b.v. - rolapitant - vomiting; nausea; cancer - anti-emetiċi u anti-nawżjanti, - prevenzjoni ta 'dardir u rimettar ittardjat assoċjati ma' kimoterapija tal-kanċer emetoġenika ħafna u moderat fl-adulti. varuby jingħata bħala parti minn terapija ta'kombinazzjoni.